Age 3 to 7 YearsAutism AnxietyNCT07060872
the Effect of Formulation on Anxiety in Autist Childre A Randomized Controlled Trial Assesses Spirulina Syrup Plus Risperidone in Children With Non-idiopathic Autism. Anxiety is Measured Using the SCAS (Parent Version) Via Daily Online Surveys for One Week and Throughout a 3-month Follow-up Period.
A study testing Spirulina Syrup and Risperidone in people with Age 3 to 7 Years and Mild Autism Spectrum, run by Shahid Sadoughi University of Medical Sciences and Health Services at 1 site in Iran.
Trial summary
The aim of this study is to evaluate the effect of a Spirulina syrup formulation on reducing anxiety in children with non-idiopathic autism. Participants are referred to a private clinic and assessed by a pediatric neurology subspecialist to confirm the diagnosis. Informed consent is obtained from the parents. Read more about this study
- Who is it for?
- Ages 3 to 7 years
- Conditions the study is for
- Age 3 to 7 Years, Mild Autism Spectrum, no Other Illness or Disorder
- What is being tested?
- Spirulina Syrup and Risperidone
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 82 participants
- Where
- 1 siteIran
- Study dates
- 7 Jul 2025to 1 Oct 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 7 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Children diagnosed with non-idiopathic autism, confirmed by a pediatric neurology subspecialist
- Age range: [3 to 7 years]
- Parental informed consent obtained
- Ability to complete online anxiety questionnaires with parental assistance
Who cannot join
- • Presence of other major neurological or psychiatric disorders
- Known allergy or intolerance to Spirulina or Risperidone
- Participation in other clinical trials within the past 3 months
- Severe medical conditions that contraindicate the use of study medications
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Randomized Controlled Interventional Study on the Effects of Spirulina Supplementation on Anxiety in Children With Non-Idiopathic Autism
The aim of this study is to evaluate the effect of a Spirulina syrup formulation on reducing anxiety in children with non-idiopathic autism. Participants are referred to a private clinic and assessed by a pediatric neurology subspecialist to confirm the diagnosis. Informed consent is obtained from the parents. Patients are randomly assigned to two groups. The intervention group receives standard treatment (Risperidone tablets) plus Spirulina syrup, while the control group receives Risperidone plus a placebo. Anxiety is measured using the parent version of the Spence Children's Anxiety Scale (SCAS), which includes 38 items rated on a 4-point Likert scale. The questionnaire is administered online via the Porsline platform, and links are sent nightly via social media starting before treatment and continuing daily for one week after treatment initiation, then regularly over a 3-month follow-up period. Data will be analyzed using SPSS version 16. The SCAS consists of six subscales: separation anxiety, social anxiety, phobia, generalized anxiety, panic, and obsessive-compulsive symptoms.
Read the detailed description
Detailed Description
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by persistent challenges in social interaction, communication, and restricted, repetitive patterns of behavior, interests, or activities. According to the latest data from the U.S. Centers for Disease Control and Prevention (CDC), approximately 1 in 54 children aged 8 years is diagnosed with ASD. The exact etiology of ASD remains unclear, but both genetic and environmental risk factors-including advanced parental age, prenatal infections, and complications during pregnancy-have been implicated.
ASD presents with a heterogeneous range of symptoms and severity. Some children may demonstrate intellectual disability, language delays, sensory sensitivities, stereotyped behaviors, and resistance to change. Others may show above-average intelligence, articulate speech, and creative talents. In addition to core symptoms, individuals with ASD often suffer from comorbidities such as anxiety, depression, gastrointestinal disturbances, and sleep problems. These comorbid conditions can significantly impair quality of life and increase the burden on families, necessitating a multidisciplinary treatment approach.
While no definitive cure for ASD currently exists, evidence-based interventions such as behavioral therapies, educational programs, and pharmacological treatments aim to manage core symptoms and associated conditions. Common pharmacologic interventions include antipsychotic medications such as risperidone to manage irritability and aggression. However, these medications often come with undesirable side effects. Consequently, there is a growing interest in complementary and alternative medicine (CAM) to support children with ASD.
Recent studies suggest that 50-95% of families with ASD-affected children explore CAM therapies, including herbal medicine, dietary supplements, and special diets. Despite limited empirical evidence, several traditional remedies have shown promise in mitigating symptoms or improving physiological functions in ASD.
In this clinical trial, we evaluate the potential anxiolytic effects of Spirulina syrup and Lemon Verbena (Lippia citriodora) syrup in children with non-idiopathic ASD. Participants are recruited from a private pediatric neurology clinic. All children are diagnosed by a pediatric neurology subspecialist, and parental informed consent is obtained before inclusion. Participants are randomized into two groups. The intervention group receives Spirulina syrup in addition to standard treatment with risperidone tablets, while the control group receives a placebo syrup with standard risperidone therapy.
Anxiety levels are measured using the Spence Children's Anxiety Scale - Parent Version (SCAS-P), which includes 38 items rated on a 4-point Likert scale (0 = never, 3 = always). This scale evaluates six subdomains: separation anxiety, social phobia, specific phobia, generalized anxiety, panic/agoraphobia, and obsessive-compulsive symptoms. The SCAS questionnaire is administered daily via the Porsline online platform. A secure link is shared with parents through social media from the week prior to intervention and continues nightly for one week after initiation. Responses are collected regularly throughout the 3-month follow-up period. Data will be analyzed using SPSS version 16.
Moreover, to evaluate the potential effectiveness of Spirulina syrup and lemon verbena (Lippia citriodora) extract in improving symptoms of Autism Spectrum Disorder (ASD), particularly in reducing anxiety symptoms, a randomized, placebo-controlled clinical trial was designed. The intervention is administered in combination with standard pharmacological therapy (Risperidone tablets) in a population of pediatric patients diagnosed with non-idiopathic autism.
This clinical study enrolls participants from a private clinic where children referred for ASD concerns are assessed by a pediatric neurology subspecialist. Inclusion criteria include children formally diagnosed with non-idiopathic ASD. After obtaining informed consent from parents, the children are randomly assigned to two groups: an intervention group receiving standard care with Risperidone and Spirulina syrup, and a control group receiving standard care with a placebo syrup.
The main outcome measure in this study is the level of anxiety, assessed using the Spence Children's Anxiety Scale (SCAS) - Parent Version. This scale consists of 38 items distributed across six subscales: separation anxiety, social anxiety, obsessive-compulsive symptoms, panic/agoraphobia, generalized anxiety, and fears of physical injury. Parents complete the SCAS via an online platform (Porsline) daily starting one week before treatment and continuing for three months following treatment initiation.
The anticipated therapeutic benefits of Spirulina and lemon verbena stem from their biochemical properties. Spirulina, a blue-green algae (Arthrospira maxima), is rich in protein, vitamins, antioxidants, and anti-inflammatory compounds. It may enhance immune function, reduce systemic inflammation, and improve oxidative stress, all of which are potentially implicated in the pathophysiology of ASD. Additionally, Spirulina has been studied for its anxiolytic effects and its potential to support cognitive performance.
Lemon verbena, a medicinal plant known for its calming effects, is traditionally used for its anxiolytic, anti-inflammatory, and digestive benefits. Bioactive compounds found in lemon verbena, such as flavonoids and phenolic acids, have demonstrated significant antioxidant and anti-inflammatory activity in prior in vitro and in vivo studies. These properties may offer additional support in addressing anxiety and gastrointestinal issues frequently seen in children with ASD.
Safety assessments include monitoring adverse events and routine clinical evaluations. Data analysis is performed using SPSS version 16. Descriptive statistics, repeated-measures ANOVA, and post-hoc tests will assess within- and between-group changes over time. The primary hypothesis is that children in the intervention group will show statistically significant reductions in anxiety symptoms compared to the control group.
This study contributes to the growing body of research into complementary and alternative medicine (CAM) approaches for ASD management. While no definitive cure for ASD currently exists, integrating safe and potentially effective natural compounds like Spirulina and lemon verbena into treatment protocols may offer additional benefits for improving the quality of life of children with ASD and their families.
Further research is warranted to validate the efficacy, safety, and mechanisms of action of these natural supplements. Should the outcomes of this clinical trial prove promising, they may lay the foundation for larger, multicenter trials and pave the way for evidence-based integration of traditional medicine with conventional ASD care practices.
- Being tested
- Spirulina Syrup, Placebo Syrup, Risperidone
- Keywords
- Autism, Anxiety, Spirulina, Pharmaceutical supplement
- Medical subject headings
- Autistic Disorder, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Spirulina SyrupDietary supplement
A natural dietary supplement derived from Spirulina algae, administered orally as a syrup formulation. Used as an adjunct therapy to assess its potential effect on reducing anxiety symptoms in children with non-idiopathic autism. Dosage and duration are standardized according to study protocol.
Placebo SyrupDietary supplement
Placebo Syrup
RisperidoneDrug
Risperidone
| Study group | Role | What they receive |
|---|---|---|
| Spirulina Syrup | Experimental | * Spirulina Syrup
* Risperidone Receives: Dietary Supplement: Spirulina Syrup; Drug: Risperidone |
| Placebo Syrup | Placebo comparator | * Placebo Syrup
* Risperidone Receives: Dietary Supplement: Placebo Syrup; Drug: Risperidone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in anxiety symptoms based on the Spence Children's Anxiety Scale (Parent Version) total score
Anxiety symptoms will be assessed using the Spence Children's Anxiety Scale (SCAS) - Parent Version, a 38-item validated tool. Total score changes will be used to evaluate treatment efficacy.
Measured: From baseline to 3 months after treatment initiation
Secondary outcomes (1)
Change in subscale scores of SCAS (e.g., separation anxiety, social anxiety, generalized anxiety, etc.)
SCAS subscale scores will be analyzed to determine which domains of anxiety are most affected by Spirulina supplementation.
Measured: From baseline to 3 months after treatment initiation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2025
- Study start7 Jul 2025 (estimated)
- Primary completion15 Sep 2025 (estimated)
- Study completion1 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Age 3 to 7 YearsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A group of 41 people took the formulation and a group of 41 people took a placebo
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 82 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shahid Sadoughi University of Medical Sciences and Health Services
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sanaz Alamdar, Shahid Sadoughi University of Medical Sciences and Health Services
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07060872
- Sponsor's protocol ID
- IR.SSU.REC
- Acronym
- Autism Anxiety
- Status last verified
- Jul 2025
- First submitted
- 2 Jul 2025
- Last updated
- 11 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Interventional Study on the Effects of Spirulina Supplementation on Anxiety in Children With Non-Idiopathic Autism
- ClinicalTrials.gov ID
- NCT07060872
- Acronym / sponsor ID
- Autism Anxiety / IR.SSU.REC
- Keywords
- Autism, Anxiety, Spirulina, Pharmaceutical supplement
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 82 participants (estimated)
- Lead sponsor
- Shahid Sadoughi University of Medical Sciences and Health ServicesUniversity, hospital or other
- Study start
- 7 Jul 2025 (estimated)
- Primary completion
- 15 Sep 2025 (estimated)
- Study completion
- 1 Oct 2025 (estimated)
- First posted
- 11 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate the effect of a Spirulina syrup formulation on reducing anxiety in children with non-idiopathic autism. Participants are referred to a private clinic and assessed by a pediatric neurology subspecialist to confirm the diagnosis. Informed consent is obtained from the parents. Patients are randomly assigned to two groups. The intervention group receives standard treatment (Risperidone tablets) plus Spirulina syrup, while the control group receives Risperidone plus a placebo. Anxiety is measured using the parent version of the Spence Children's Anxiety Scale (SCAS), which includes 38 items rated on a 4-point Likert scale. The questionnaire is administered online via the Porsline platform, and links are sent nightly via social media starting before treatment and continuing daily for one week after treatment initiation, then regularly over a 3-month follow-up period. Data will be analyzed using SPSS version 16. The SCAS consists of six subscales: separation anxiety, social anxiety, phobia, generalized anxiety, panic, and obsessive-compulsive symptoms.
Detailed description
Detailed Description
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by persistent challenges in social interaction, communication, and restricted, repetitive patterns of behavior, interests, or activities. According to the latest data from the U.S. Centers for Disease Control and Prevention (CDC), approximately 1 in 54 children aged 8 years is diagnosed with ASD. The exact etiology of ASD remains unclear, but both genetic and environmental risk factors-including advanced parental age, prenatal infections, and complications during pregnancy-have been implicated.
ASD presents with a heterogeneous range of symptoms and severity. Some children may demonstrate intellectual disability, language delays, sensory sensitivities, stereotyped behaviors, and resistance to change. Others may show above-average intelligence, articulate speech, and creative talents. In addition to core symptoms, individuals with ASD often suffer from comorbidities such as anxiety, depression, gastrointestinal disturbances, and sleep problems. These comorbid conditions can significantly impair quality of life and increase the burden on families, necessitating a multidisciplinary treatment approach.
While no definitive cure for ASD currently exists, evidence-based interventions such as behavioral therapies, educational programs, and pharmacological treatments aim to manage core symptoms and associated conditions. Common pharmacologic interventions include antipsychotic medications such as risperidone to manage irritability and aggression. However, these medications often come with undesirable side effects. Consequently, there is a growing interest in complementary and alternative medicine (CAM) to support children with ASD.
Recent studies suggest that 50-95% of families with ASD-affected children explore CAM therapies, including herbal medicine, dietary supplements, and special diets. Despite limited empirical evidence, several traditional remedies have shown promise in mitigating symptoms or improving physiological functions in ASD.
In this clinical trial, we evaluate the potential anxiolytic effects of Spirulina syrup and Lemon Verbena (Lippia citriodora) syrup in children with non-idiopathic ASD. Participants are recruited from a private pediatric neurology clinic. All children are diagnosed by a pediatric neurology subspecialist, and parental informed consent is obtained before inclusion. Participants are randomized into two groups. The intervention group receives Spirulina syrup in addition to standard treatment with risperidone tablets, while the control group receives a placebo syrup with standard risperidone therapy.
Anxiety levels are measured using the Spence Children's Anxiety Scale - Parent Version (SCAS-P), which includes 38 items rated on a 4-point Likert scale (0 = never, 3 = always). This scale evaluates six subdomains: separation anxiety, social phobia, specific phobia, generalized anxiety, panic/agoraphobia, and obsessive-compulsive symptoms. The SCAS questionnaire is administered daily via the Porsline online platform. A secure link is shared with parents through social media from the week prior to intervention and continues nightly for one week after initiation. Responses are collected regularly throughout the 3-month follow-up period. Data will be analyzed using SPSS version 16.
Moreover, to evaluate the potential effectiveness of Spirulina syrup and lemon verbena (Lippia citriodora) extract in improving symptoms of Autism Spectrum Disorder (ASD), particularly in reducing anxiety symptoms, a randomized, placebo-controlled clinical trial was designed. The intervention is administered in combination with standard pharmacological therapy (Risperidone tablets) in a population of pediatric patients diagnosed with non-idiopathic autism.
This clinical study enrolls participants from a private clinic where children referred for ASD concerns are assessed by a pediatric neurology subspecialist. Inclusion criteria include children formally diagnosed with non-idiopathic ASD. After obtaining informed consent from parents, the children are randomly assigned to two groups: an intervention group receiving standard care with Risperidone and Spirulina syrup, and a control group receiving standard care with a placebo syrup.
The main outcome measure in this study is the level of anxiety, assessed using the Spence Children's Anxiety Scale (SCAS) - Parent Version. This scale consists of 38 items distributed across six subscales: separation anxiety, social anxiety, obsessive-compulsive symptoms, panic/agoraphobia, generalized anxiety, and fears of physical injury. Parents complete the SCAS via an online platform (Porsline) daily starting one week before treatment and continuing for three months following treatment initiation.
The anticipated therapeutic benefits of Spirulina and lemon verbena stem from their biochemical properties. Spirulina, a blue-green algae (Arthrospira maxima), is rich in protein, vitamins, antioxidants, and anti-inflammatory compounds. It may enhance immune function, reduce systemic inflammation, and improve oxidative stress, all of which are potentially implicated in the pathophysiology of ASD. Additionally, Spirulina has been studied for its anxiolytic effects and its potential to support cognitive performance.
Lemon verbena, a medicinal plant known for its calming effects, is traditionally used for its anxiolytic, anti-inflammatory, and digestive benefits. Bioactive compounds found in lemon verbena, such as flavonoids and phenolic acids, have demonstrated significant antioxidant and anti-inflammatory activity in prior in vitro and in vivo studies. These properties may offer additional support in addressing anxiety and gastrointestinal issues frequently seen in children with ASD.
Safety assessments include monitoring adverse events and routine clinical evaluations. Data analysis is performed using SPSS version 16. Descriptive statistics, repeated-measures ANOVA, and post-hoc tests will assess within- and between-group changes over time. The primary hypothesis is that children in the intervention group will show statistically significant reductions in anxiety symptoms compared to the control group.
This study contributes to the growing body of research into complementary and alternative medicine (CAM) approaches for ASD management. While no definitive cure for ASD currently exists, integrating safe and potentially effective natural compounds like Spirulina and lemon verbena into treatment protocols may offer additional benefits for improving the quality of life of children with ASD and their families.
Further research is warranted to validate the efficacy, safety, and mechanisms of action of these natural supplements. Should the outcomes of this clinical trial prove promising, they may lay the foundation for larger, multicenter trials and pave the way for evidence-based integration of traditional medicine with conventional ASD care practices.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- A group of 41 people took the formulation and a group of 41 people took a placebo
| Arm | Type | Receives |
|---|---|---|
| Spirulina Syrup | Experimental | Dietary Supplement: Spirulina Syrup, Drug: Risperidone* Spirulina Syrup * Risperidone |
| Placebo Syrup | Placebo comparator | Dietary Supplement: Placebo Syrup, Drug: Risperidone* Placebo Syrup * Risperidone |
Who may qualify
- Ages
- 3 to 7 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Children diagnosed with non-idiopathic autism, confirmed by a pediatric neurology subspecialist
Key exclusion criteria (4 listed)
- • Presence of other major neurological or psychiatric disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Spirulina SyrupA natural dietary supplement derived from Spirulina algae, administered orally as a syrup formulation. Used as an adjunct therapy to assess its potential effect on reducing anxiety symptoms in children with non-idiopathic autism. Dosage and duration are standardized according to study protocol. | Dietary supplement | Spirulina Syrup |
| Placebo SyrupPlacebo Syrup | Dietary supplement | Placebo Syrup |
| RisperidoneRisperidone | Drug | Placebo Syrup, Spirulina Syrup |
Primary outcome
Change in anxiety symptoms based on the Spence Children's Anxiety Scale (Parent Version) total score
Time frame: From baseline to 3 months after treatment initiation
Anxiety symptoms will be assessed using the Spence Children's Anxiety Scale (SCAS) - Parent Version, a 38-item validated tool. Total score changes will be used to evaluate treatment efficacy.
1 secondary outcome
Change in subscale scores of SCAS (e.g., separation anxiety, social anxiety, generalized anxiety, etc.)
Time frame: From baseline to 3 months after treatment initiation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jul 2025.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Age 3 to 7 Years
RecruitingPhase 3
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
Lyme Disease
Not yet recruiting
Disclosing Agents as Photosensitizers in aPDT for Biofilm Control in Children
Dental Plaque
Active, not recruitingPhase 3
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
Allergy, Peanut
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Spirulina Syrup and Risperidone in people with Age 3 to 7 Years and Mild Autism Spectrum, run by Shahid Sadoughi University of Medical Sciences and Health Services at 1 site in Iran.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iran. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sanaz Alamdar, M.s (+989132738977, Sani.deol1@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in anxiety symptoms based on the Spence Children's Anxiety Scale (Parent Version) total score (time frame: From baseline to 3 months after treatment initiation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2025.